Search Browse Earnings

Coherus Oncology, Inc. — SlamSEC

Coherus Oncology, Inc.

Nasdaq:CHRS

Biological Products, (No Diagnostic Substances)·REDWOOD CITY, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$0

-100.0% YoY

FY 2019

Adj. EBITDA

-$198.1M

FY 2025

Net Income

$28.5M

FY 2025

EPS (Diluted)

$0.25

FY 2025

Stock Price

$1.95

+7.1%

2026-03-10

52W Range

$0.71 – $2.62

P/E Ratio

7.8x

Market Cap

$292.1M

Cash

$126.0M

FY 2025

Total Debt

—

Net Cash

$126.0M

FY 2019

Enterprise Value

$166.1M

Debt / EBITDA

0.6x

FY 2019

EV / EBITDA

-0.8x

Employees

—